(IO-102 + IO-103) is under clinical development by IO Biotech and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (IO-102 + IO-103)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(IO-102 + IO-103) overview

PD-L1/IDO (IO102/IO103) peptide vaccine is under development for the treatment of melanoma, metastatic melanoma, head and neck cancer and non muscle invasive bladder cancer (NMIBC), metastatic non-small cell lung cancer (NSCLC), squamous cell carcinoma of head or neck (SCCHN), metastatic urothelial bladder cancer (mUBC), ureter cancer, kidney cancer (renal cell cancer), bladder cancer, urethral cancer, transitional cell carcinoma (urothelial cell carcinoma), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer and metastatic solid tumors. It comprises of programmed cell death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase (IDO) peptides. It acts by targeting PD-L1 and IDO. It is developed based on T-win technology. It is administered through subcutaneous route.

IO Biotech overview

IO Biotech is a biotechnology company, which develops disruptive immune modulating anti-cancer drugs. The company is investigating IO102 vaccine, against non-small cell lung cancer (NSCLC); IO130, a PD-L1 inhibitor targeting basal cell carcinoma of the skin; IO112 vaccine, to treat solid tumors; IO140, an immune modulatory vaccine containing a single CCL22 derived peptide, against ovarian cancer; and IO160, a neo antigen vaccine to treat myeloproliferative neoplasms (MPN). It utilizes T-win technology platform to discover, design, and validate new immune modulating vaccine candidates. The company is a spin off from the Center for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital. IO Biotech is headquartered in Copenhagen, Denmark.

For a complete picture of (IO-102 + IO-103)’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.